160.25 -0.47 (-0.29%)
Pre-Market: 4:21AM EST
|Bid||152.00 x 200|
|Ask||152.98 x 300|
|Day's Range||159.39 - 162.07|
|52 Week Range||84.39 - 174.96|
|PE Ratio (TTM)||154.69|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||192.24|
A trio of investors has identified Vertex Pharmaceuticals, Proofpoint, and Baozun as companies capable of delivering better returns to shareholders from here than the e-commerce giant.
Vertex Pharmaceuticals has unveiled promising findings from a study of one of its experimental drugs — only this time, the treatment doesn’t target cystic fibrosis. Boston-based Vertex (VRTX), which largely focuses on the lung disorder, said Wednesday that its non-opioid medicine for pain had performed well in a mid-stage study. Patients who received the drug, called VX-150, following surgery to remove bunions reported significant pain relief compared to those on placebo, according to the company.
Vertex Pharmaceuticals Incorporated today announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery.
Payers likely won't balk at the yearly price for Vertex's new two-drug regimen to treat some cystic fibrosis patients, analysts said Tuesday.
Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.
Stocks threatened to snap the market's two-day advance early Tuesday, despite strong early action among leading Chinese names.
Vertex Pharmaceuticals said Monday that the FDA has approved its third drug for cystic fibrosis, lifting shares of the Boston-based company. Vertex (VRTX) said the drug — a combination of Kalydeco, which was approved in 2012, and a new medicine called tezacaftor — will be sold under the brand name Symdeko. "This approval is an important milestone in our journey to treat every person with CF, and we remain committed to urgently advancing our efforts to develop new medicines that treat the underlying cause of CF for the many people still waiting," Vertex CEO Jeffrey Leiden said in a statement.
Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) climbed nearly 2% in after-hours trading Monday after the U.S. Food and Drug Administration approved SYMDEKO, the drugmaker’s third medicine to treat the underlying cause of CF. Vertex is ready to launch SYMDEKO and will begin shipping it to pharmacies in the US this week. The approval of SYMDEKO, our third disease-modifying CF medicine, offers many patients an important new treatment option," said Jeffrey Leiden, M.D., Ph.D., Vertex's Chairman, President and Chief Executive Officer. "We've already seen the significant impact that disease-modifying medicines can have on patients and are incredibly pleased that there is now a third treatment option that enables more patients to benefit from CFTR modulation," said Patrick Flume, M.D., Director of the Medical University of South Carolina Cystic Fibrosis Center and Principal Investigator for the EXTEND study.
The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc's Kalydeco with another medicine, Vertex said, marking the company's third product for the life-shortening lung disorder. Vertex shares rose about 2 percent to $154.92 in extended trading after the approval was announced about two weeks ahead of an expected FDA action date. The treatment, which will be sold under the brand name Symdeko, will carry a list price of $292,000 per year, Vertex announced, placing it between its previously approved CF treatments, Kalydeco and Orkambi.
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration approved SYMDEKO™ for treating the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor.
After trouncing the market in 2017, these biopharma heavyweights are taking it on the chin. Is one a better stock to buy than the other?
The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services
Celgene, Vertex and Incyte could have entry points amid a broader market correction, an analyst said Tuesday.
Vertex Pharmaceuticals, Atlassian, iPhone chipmaker Qorvo and other top stocks in recent days fell slightly below buy points. Why you should keep them on your radar.
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Bristol Myers Squibb reported earnings that beat on earnings and revenue.